药物信息为MDP-BRACCO™ Kit for the Preparation of Technetium Tc 99m Medronate (Bracco Diagnostics Inc.): DESCRIPTION
- DESCRIPTION
- PHYSICAL CHARACTERISTICS
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- 外部链接相关的MDP-BRACCO™ Kit for the Preparation of Technetium Tc 99m Medronate (Bracco Diagnostics Inc.)
Each reaction vial contains a sterile, nonpyrogenic, nonradioactive lyophilized mixture of 20 mg medronic acid, 11 mg sodium hydroxide, 1 mg ascorbic acid, 0.13 mg (minimum) stannous fluoride, SnF2 and 0.38 mg total tin, maximum (as stannous fluoride, SnF2).
The pH is adjusted with sodium hydroxide or hydrochloric acid to 6.5 (6.3 to 6.7) prior to lyophilization. The vial does not contain a preservative. The contents of the vial are lyophilized and sealed under nitrogen at the time of manufacture.
The pH of the reconstituted product is 5.4 to 6.8.
The structure of medronic acid is given below:

The precise structure of technetium Tc 99m medronate is unknown at this time.
When sterile, pyrogen-free sodium pertechnetate Tc 99m injection is added to the vial, the diagnostic agent technetium Tc 99m medronate is formed for administration by intravenous injection.
- Drug Information Provided by National Library of Medicine (NLM).
